DDInter1340 DDInter119
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Omeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
Omeprazole {u} (Compound) palliates {v} (Disease) systemic scleroderma
Omeprazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Omeprazole {u} (Compound) downregulates {v} (Gene) THAP11
Omeprazole {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Omeprazole (Compound) resembles Pantoprazole (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound)
Omeprazole (Compound) treats Barrett's esophagus (Disease)
Omeprazole (Compound) binds CYP1A2 (Gene)
Omeprazole (Compound) upregulates TIPARP (Gene)
Omeprazole (Compound) palliates systemic scleroderma (Disease)
Omeprazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Omeprazole (Compound) downregulates THAP11 (Gene)
Omeprazole (Compound) causes Alanine aminotransferase increased (Side Effect)